4//SEC Filing
Nantahala Capital Management, LLC 4
Accession 0001104659-24-072893
CIK 0001385818other
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 5:09 PM ET
Size
12.7 KB
Accession
0001104659-24-072893
Insider Transaction Report
Form 4
Harkey Wilmot B.
10% Owner
Transactions
- Exercise of In-Money
Tranche B Warrant
2024-06-14−815,217→ 0 total(indirect: See Footnote)Exercise: $1.59→ Common Stock (815,217 underlying) - Exercise of In-Money
Exchange Warrants
2024-06-14+815,217→ 815,217 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (815,217 underlying)
Nantahala Capital Management, LLC
10% Owner
Transactions
- Exercise of In-Money
Tranche B Warrant
2024-06-14−815,217→ 0 total(indirect: See Footnote)Exercise: $1.59→ Common Stock (815,217 underlying) - Exercise of In-Money
Exchange Warrants
2024-06-14+815,217→ 815,217 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (815,217 underlying)
Mack Daniel
10% Owner
Transactions
- Exercise of In-Money
Tranche B Warrant
2024-06-14−815,217→ 0 total(indirect: See Footnote)Exercise: $1.59→ Common Stock (815,217 underlying) - Exercise of In-Money
Exchange Warrants
2024-06-14+815,217→ 815,217 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (815,217 underlying)
Footnotes (3)
- [F1]The Tranche B Warrants may be exercised for either shares of Common Stock or Exchange Warrants. Subject to certain limits on beneficial ownership, the Tranche B Warrants are exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Issuer's achievement of consolidated trailing twelve-month adjusted EBITDA of $12 million.
- [F2]Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Aytu BioPharma, Inc ("Issuer") securities disclosed in this Form 4, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
- [F3]Subject to certain limits on beneficial ownership, the Exchange Warrants may be exercised to purchase Issuer Common Stock at an exercise price of $0.0001 per share. The Exchange Warrants do not expire until exercised in full.
Documents
Issuer
AYTU BIOPHARMA, INC
CIK 0001385818
Entity typeother
IncorporatedMA
Related Parties
1- filerCIK 0001472322
Filing Metadata
- Form type
- 4
- Filed
- Jun 17, 8:00 PM ET
- Accepted
- Jun 18, 5:09 PM ET
- Size
- 12.7 KB